Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 215

Similar articles for PubMed (Select 23414474)

1.

Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.

Bradish JR, Montironi R, Lopez-Beltran A, Post KM, MacLennan GT, Cheng L.

Future Oncol. 2013 Feb;9(2):245-53. doi: 10.2217/fon.12.179. Review.

PMID:
23414474
2.

Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.

Chraybi M, Abd Alsamad I, Copie-Bergman C, Baia M, André J, Dumaz N, Ortonne N.

Hum Pathol. 2013 Sep;44(9):1902-11. doi: 10.1016/j.humpath.2013.01.025. Epub 2013 May 9.

3.

KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.

Zebary A, Omholt K, Vassilaki I, Höiom V, Lindén D, Viberg L, Kanter-Lewensohn L, Johansson CH, Hansson J.

J Dermatol Sci. 2013 Dec;72(3):284-9. doi: 10.1016/j.jdermsci.2013.07.013. Epub 2013 Aug 8.

PMID:
23993026
4.

Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes.

Henary H, Hong DS, Falchook GS, Tsimberidou A, George GC, Wen S, Wheler J, Fu S, Naing A, Piha-Paul S, Janku F, Kim KB, Hwu P, Kurzrock R.

Ann Oncol. 2013 Aug;24(8):2158-65. doi: 10.1093/annonc/mdt115. Epub 2013 Apr 10.

5.

Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site.

Gos A, Jurkowska M, van Akkooi A, Robert C, Kosela-Paterczyk H, Koljenović S, Kamsukom N, Michej W, Jeziorski A, Pluta P, Verhoef C, Siedlecki JA, Eggermont AM, Rutkowski P.

Ann Surg Oncol. 2014 Dec;21(13):4317-23. doi: 10.1245/s10434-014-3799-y. Epub 2014 May 28.

6.

KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases.

Zebary A, Jangard M, Omholt K, Ragnarsson-Olding B, Hansson J.

Br J Cancer. 2013 Aug 6;109(3):559-64. doi: 10.1038/bjc.2013.373. Epub 2013 Jul 16.

7.

[Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].

Lázár V.

Magy Onkol. 2013 Jun;57(2):96-9. doi: MagyOnkol.2013.57.2.96. Epub 2013 May 20. Hungarian.

8.

Targeting BRAF in melanoma: biological and clinical challenges.

Mandalà M, Voit C.

Crit Rev Oncol Hematol. 2013 Sep;87(3):239-55. doi: 10.1016/j.critrevonc.2013.01.003. Epub 2013 Feb 15. Review.

PMID:
23415641
9.

Molecular targeted approaches for advanced BRAF V600, N-RAS, c-KIT, and GNAQ melanomas.

Ponti G, Pellacani G, Tomasi A, Loschi P, Luppi G, Gelsomino F, Longo C.

Dis Markers. 2014;2014:671283. doi: 10.1155/2014/671283. Epub 2014 Jan 23. Erratum in: Dis Markers. 2014;2014:246751. Giovanni, Ponti [corrected to Ponti, Giovanni]; Giovanni, Pellacani [corrected to Pellacani, Giovanni]; Aldo, Tomasi [corrected to Tomasi, Aldo]; Pietro, Loschi [corrected to Loschi, Pietro]; Gabriele, Luppi [corrected to Luppi, Gabriele]; Fabio, Gelsomino [corrected to Gelsomino, Fabio]; Caterina, Longo [corrected to Longo, Caterina].

10.

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.

Niessner H, Forschner A, Klumpp B, Honegger JB, Witte M, Bornemann A, Dummer R, Adam A, Bauer J, Tabatabai G, Flaherty K, Sinnberg T, Beck D, Leiter U, Mauch C, Roesch A, Weide B, Eigentler T, Schadendorf D, Garbe C, Kulms D, Quintanilla-Martinez L, Meier F.

Cancer Med. 2013 Feb;2(1):76-85. doi: 10.1002/cam4.50. Epub 2013 Feb 3.

11.

NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.

van Engen-van Grunsven AC, Küsters-Vandevelde HV, De Hullu J, van Duijn LM, Rijntjes J, Bovée JV, Groenen PJ, Blokx WA.

Gynecol Oncol. 2014 Jul;134(1):10-4. doi: 10.1016/j.ygyno.2014.04.056. Epub 2014 May 5.

PMID:
24802725
12.

Beyond BRAF: where next for melanoma therapy?

Fedorenko IV, Gibney GT, Sondak VK, Smalley KS.

Br J Cancer. 2015 Jan 20;112(2):217-26. doi: 10.1038/bjc.2014.476. Epub 2014 Sep 2. Review.

13.

The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.

Ekedahl H, Cirenajwis H, Harbst K, Carneiro A, Nielsen K, Olsson H, Lundgren L, Ingvar C, Jönsson G.

Br J Dermatol. 2013 Nov;169(5):1049-55. doi: 10.1111/bjd.12504.

PMID:
23855428
14.

Treatment implications of the emerging molecular classification system for melanoma.

Romano E, Schwartz GK, Chapman PB, Wolchock JD, Carvajal RD.

Lancet Oncol. 2011 Sep;12(9):913-22. doi: 10.1016/S1470-2045(10)70274-6. Epub 2011 Feb 23. Review.

PMID:
21349766
15.

Targeted therapy for melanoma: rational combinatorial approaches.

Kwong LN, Davies MA.

Oncogene. 2014 Jan 2;33(1):1-9. doi: 10.1038/onc.2013.34. Epub 2013 Feb 18. Review.

PMID:
23416974
16.

Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.

Schlaak M, Bajah A, Podewski T, Kreuzberg N, von Bartenwerffer W, Wardelmann E, Merkelbach-Bruse S, Büttner R, Mauch C, Kurschat P.

Br J Dermatol. 2013 Apr;168(4):708-16. doi: 10.1111/bjd.12140.

PMID:
23528057
17.

Recent advances in cutaneous melanoma: towards a molecular model and targeted treatment.

Read J.

Australas J Dermatol. 2013 Aug;54(3):163-72. doi: 10.1111/ajd.12013. Epub 2013 Jan 18. Review.

PMID:
23330781
18.

KIT, NRAS, and BRAF mutations in nail apparatus melanoma.

Dika E, Altimari A, Patrizi A, Gruppioni E, Fiorentino M, Piraccini BM, Misciali C, Barisani A, Fanti PA.

Pigment Cell Melanoma Res. 2013 Sep;26(5):758-60. doi: 10.1111/pcmr.12123. Epub 2013 Jun 20. No abstract available.

PMID:
23782496
19.

BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.

Mar VJ, Wong SQ, Li J, Scolyer RA, McLean C, Papenfuss AT, Tothill RW, Kakavand H, Mann GJ, Thompson JF, Behren A, Cebon JS, Wolfe R, Kelly JW, Dobrovic A, McArthur GA.

Clin Cancer Res. 2013 Sep 1;19(17):4589-98. doi: 10.1158/1078-0432.CCR-13-0398. Epub 2013 Jul 5.

20.

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.

Carlino MS, Haydu LE, Kakavand H, Menzies AM, Hamilton AL, Yu B, Ng CC, Cooper WA, Thompson JF, Kefford RF, O'Toole SA, Scolyer RA, Long GV.

Br J Cancer. 2014 Jul 15;111(2):292-9. doi: 10.1038/bjc.2014.287. Epub 2014 Jun 10.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk